FDA Inspection 1013712 — Fresenius Kabi Oncology Limited
The FDA completed an inspection of Fresenius Kabi Oncology Limited on May 24, 2017 in Nadia. The inspection was classified OAI (Official Action Indicated — objectionable conditions were found and regulatory action is recommended). Product area: Drugs.
Inspection Details
- Classification
- Official Action Indicated (OAI) (OAI)
- End Date
- May 24, 2017
- Fiscal Year
- 2017
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Nadia (India)